The capacity to consent to treatment in amyotrophic lateral sclerosis: a preliminary report

[1] Charcot JM(1874)De la sclérose latérale amyotrophique Prog Med 2 325-327

[2] Goldstein LH(2013)Change in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment Lancet Neurol 12 368-380

[3] Abrahams S(2005)Frontotemporal dementia progresses to death faster than Alzheimer disease Neurology 65 719-725

[4] Robertson ED(2010)A prospective cohort study of neuropsychological test performance in ALS Amyotroph Lateral Scler 11 312-320

[5] Hesse JH(2011)Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia Neurology 76 1263-1269

[6] Rose KD(2012)Neurobehavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV Neurology 78 1085-1089

[7] Gordon PH(1988)Assessing patients’ capacity to consent to treatment N Engl J Med 319 1635-1638

[8] Goetz RR(1994)Determining the competency of Alzheimer’s patients to consent to treatment and research Alzheimer Dis Assoc Disord 8 5-18

[9] Rabkin JG(1996)Toward a neurologic model of competency: cognitive predictors of capacity to consent in Alzheimer’s disease using three different legal standards Neurology 46 666-672

[10] Elamin M(2006)Declining medical decision-making capacity in mild AD: a two-year longitudinal study Behav Sci Law 24 453-463

[1] Charcot JM(1874)De la sclérose latérale amyotrophique Prog Med 2 325-327

[2] Goldstein LH(2013)Change in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment Lancet Neurol 12 368-380

[3] Abrahams S(2005)Frontotemporal dementia progresses to death faster than Alzheimer disease Neurology 65 719-725

[4] Robertson ED(2010)A prospective cohort study of neuropsychological test performance in ALS Amyotroph Lateral Scler 11 312-320

[5] Hesse JH(2011)Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia Neurology 76 1263-1269

[6] Rose KD(2012)Neurobehavioral dysfunction in ALS has a negative effect on outcome and use of PEG and NIV Neurology 78 1085-1089

[7] Gordon PH(1988)Assessing patients’ capacity to consent to treatment N Engl J Med 319 1635-1638

[8] Goetz RR(1994)Determining the competency of Alzheimer’s patients to consent to treatment and research Alzheimer Dis Assoc Disord 8 5-18

[9] Rabkin JG(1996)Toward a neurologic model of competency: cognitive predictors of capacity to consent in Alzheimer’s disease using three different legal standards Neurology 46 666-672

[10] Elamin M(2006)Declining medical decision-making capacity in mild AD: a two-year longitudinal study Behav Sci Law 24 453-463